Senores Pharmaceuticals Appoints New Senior Management, Announces Resignation
Senores Pharmaceuticals Limited announced changes to its senior management on Tuesday, March 17, 2026. The company’s Board of Directors approved the appointment of Mr. Jatin Gajjar as a Senior Management Personnel (SMP) and Chief Technology Officer. Mr. Gajjar brings over three decades of leadership experience in pharmaceutical technology, manufacturing operations, and product development.Simultaneously, the company announced that Mr. Manohar Lalge, President - Research and Development, has resigned, effective March 17, 2026. He is also stepping down as an SMP of the company.
According to a company statement, Mr. Gajjar’s expertise lies in complex formulations, regulatory compliance, and process optimization. He previously held leadership roles at various pharmaceutical organizations, including Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma. He holds degrees in Pharmacy from L.M. College of Pharmacy, Gujarat University.
Brief Profile of Mr. Jatin Gajjar:
| Particulars | Details |
|---|---|
| Reason for Change | Appointment of Mr. Jatin Gajjar as SMP |
| Date of Appointment | March 17, 2026 |
| Brief Profile | Mr. Jatin Gajjar serves as Chief Technology Officer, bringing over three decades of leadership experience in pharmaceutical technology, manufacturing operations, and product development. His expertise is in complex formulations, regulatory compliance, and process optimization. |
Regarding Mr. Lalge’s departure:
| Particulars | Details |
|---|---|
| Reason for Change | Resignation of Mr. Manohar Lalge as SMP |
| Date of Cessation | March 17, 2026 |
Further details regarding these changes are available on the company’s website at www.senorespharma.com.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.